Stone metabolic clinic · KIMS Secunderabad
Nephrocalcinosis — Calcium Deposits in the Kidneys: Causes and Management
Nephrocalcinosis is the deposition of calcium salts — primarily calcium phosphate and calcium oxalate — within the renal parenchyma (the functional tissue of the kidney), as distinct from kidney stones which form within the collecting system (calyces, renal pelvis, ureter). It is a radiological finding — visible on plain X-ray, renal ultrasound, or CT — that indicates an underlying metabolic disorder causing chronic calcium or phosphate dysregulation in the kidney. Left unidentified and untreated, the underlying cause continues to deposit calcium, progressively damaging tubular cells, causing interstitial fibrosis, and contributing to CKD.
Nephrocalcinosis is classified anatomically into medullary nephrocalcinosis (far more common — calcium deposits within the medullary pyramids) and cortical nephrocalcinosis (rare — calcium deposits in the renal cortex, typically from severe cortical necrosis, chronic glomerulonephritis, or oxalosis). The clinical evaluation always focuses on identifying the underlying metabolic cause — because the calcium deposits themselves are the consequence, not the disease.
Causes — the important conditions to identify
Distal renal tubular acidosis (Type 1 RTA) — the most important cause
Very common in metabolic stone clinics. Clinical clues: Persistent urine pH above 5.5 despite metabolic acidosis · Hypokalaemia · Calcium phosphate stones · Family history of kidney stones · Medullary nephrocalcinosis on imaging. Diagnostic tests: Urine anion gap positive. Treatment: Potassium citrate is curative.
Primary hyperparathyroidism
Elevated PTH from parathyroid adenoma. Common in adults above 50, more common in women. Clinical clues: Hypercalcaemia (calcium above 2.6 mmol/L) · Hypophosphataemia · Elevated PTH · Often asymptomatic — detected incidentally on blood tests · Renal stones and nephrocalcinosis · Bone loss on DEXA. Diagnostic tests: Sestamibi scan localises parathyroid adenoma. Treatment: parathyroidectomy.
Medullary sponge kidney (MSK)
Common in recurrent stone patients. Clinical clues: Collecting duct ectasia on IVU or CT urogram · Medullary calcifications · Often with concurrent Type 1 RTA. Diagnostic tests / treatment: Metabolic stone clinic workup.
Hyperoxaluria (primary and enteric)
Important in India. Clinical clues: Elevated 24-hour urine oxalate · Calcium oxalate stones · In primary hyperoxaluria: systemic oxalosis (deposits in heart, bone, eyes). Diagnostic tests: Genetic testing for PH1/PH2/PH3.
Hypervitaminosis D
From excess vitamin D supplementation. Clinical clues: Hypercalcaemia · Elevated 25-OH vitamin D · History of high-dose vitamin D supplement use · Hypercalciuria. Treatment: Reduce vitamin D dose, hydration, calcitonin.
Sarcoidosis
Causes granulomatous hypercalcaemia. Clinical clues: Elevated 1,25-OH vitamin D (activated by sarcoid granulomas) · Elevated ACE level · Hilar lymphadenopathy on chest X-ray. Treatment: Low dose corticosteroids reduce calcium.
Bartter syndrome and other tubular disorders
Rare. Clinical clues: Hypokalaemia · Metabolic alkalosis · Polyuria from childhood · Renal salt wasting.
Investigations at KIMS
Serum calcium, phosphate, magnesium — identifies hypercalcaemia and hypophosphataemia (hyperparathyroidism), hyperphosphataemia (CKD-related), or hypomagnesaemia (tubular disorders).
Serum PTH (intact PTH) — elevated in primary hyperparathyroidism and secondary hyperparathyroidism (CKD). Suppressed in vitamin D toxicity and sarcoidosis-related hypercalcaemia.
Serum 25-OH vitamin D and 1,25-OH vitamin D — vitamin D toxicity (excess 25-OH) vs granulomatous activation (elevated 1,25-OH with normal 25-OH in sarcoidosis).
24-hour urine calcium, oxalate, citrate, pH — quantifies the stone-forming risk and identifies the specific metabolic abnormality (hypercalciuria, hyperoxaluria, hypocitraturia, RTA).
Urine anion gap and pH — confirms Type 1 RTA (positive UAG, urine pH above 5.5 despite acidaemia).
ACE level — elevated in sarcoidosis.
Renal ultrasound and plain X-ray — identifies the extent of nephrocalcinosis. Medullary echogenicity on ultrasound correlates with medullary calcium deposition.
Treatment
Treatment is directed at the underlying cause — the calcium deposits cannot be directly dissolved or removed. Success is measured by halting further calcium deposition (preventing progression) and protecting kidney function.
Type 1 RTA
Potassium citrate corrects the metabolic acidosis, raises urinary citrate, and normalises urinary pH — stopping further calcium phosphate precipitation. The most treatable cause.
Primary hyperparathyroidism
Parathyroidectomy normalises PTH, calcium, and urinary calcium excretion. Nephrocalcinosis stabilises after surgery; established deposits do not resorb.
Hypervitaminosis D
Stop supplementation, hydration, corticosteroids or calcitonin for severe hypercalcaemia.
Sarcoidosis
Low-dose prednisolone reduces the granulomatous 1,25-OH vitamin D activation, lowering serum and urine calcium.
General measures
High fluid intake (above 2.5 litres daily), dietary calcium moderation (normal intake — not restriction), avoidance of vitamin D over-supplementation.
Book a Metabolic Stone and Nephrocalcinosis Assessment at KIMS
Frequently Asked Questions — Nephrocalcinosis
No — they are related but distinct. Kidney stones (nephrolithiasis) form within the collecting system — the calyces, renal pelvis, and ureter — and can move, causing renal colic and obstruction. Nephrocalcinosis is calcium deposition within the kidney parenchyma — the actual tissue of the kidney — not in the collecting spaces. However, both can coexist (and frequently do, particularly in RTA, MSK, and hyperparathyroidism), and both share the same underlying metabolic abnormalities. Nephrocalcinosis causes more direct parenchymal damage than stones in the collecting system, because the calcium deposits directly injure adjacent tubular cells and trigger interstitial inflammation.
Established calcium deposits in the renal parenchyma are largely irreversible — calcium phosphate and calcium oxalate crystals that have formed within the interstitium and tubular cells do not dissolve with treatment. However, treatment of the underlying cause stops further deposition and prevents progression. In early nephrocalcinosis — particularly from Type 1 RTA treated with potassium citrate — some reduction in nephrocalcinosis extent has been reported on serial imaging, likely from partial dissolution of small deposits in the treated (now less alkaline and more citrate-rich) urine environment. The primary goal of treatment is stabilisation, not reversal.
Severe or untreated nephrocalcinosis can contribute to progressive CKD — the calcium deposits trigger interstitial fibrosis and tubular atrophy, reducing functional kidney mass over years. The rate of progression depends on the underlying cause, the extent of existing deposits, and the success of treatment in halting further deposition. Type 1 RTA treated early with potassium citrate typically maintains normal kidney function indefinitely. Hyperoxaluria PH1 with systemic oxalosis — the most severe form — commonly progresses to ESRD before age 30 if untreated.
On renal ultrasound, medullary nephrocalcinosis appears as increased echogenicity (brighter than normal) of the medullary pyramids — the triangular zones of the inner kidney visible on ultrasound. In normal kidneys, the medullary pyramids appear slightly darker than the cortex. In nephrocalcinosis, calcium deposits in the medullary tubules increase their echogenicity, making them appear brighter than the cortex or as echogenic foci within each pyramid. In severe nephrocalcinosis, the medullary pyramids may appear uniformly bright with posterior acoustic shadowing. Plain X-ray shows the medullary calcifications as ring-like or irregular opacities in the distribution of the medullary pyramids.
KIMS Secunderabad — Dr. V. S. Reddy (Senior Consultant Nephrologist), metabolic stone clinic with 24-hour urine calcium, oxalate, citrate, pH and urine anion gap, serum PTH, vitamin D, ACE, genetic testing for primary hyperoxaluria, potassium citrate protocol for RTA-related nephrocalcinosis, parathyroid surgery coordination for primary hyperparathyroidism. NABH and NABL accredited. Call 040-4488-5000.